Reata, Kyowa Kirin End Bardoxolone CKD Development

Missed Secondary Endpoint In Japan Trial

 
• By Lisa Takagi
  
Kyowa Kirin / Reata
Kyowa Kirin’s decision to withdraw from Japanese development set to impact bardoxolone’s US pathway • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Japan

More from Focus On Asia